Journal
CANCERS
Volume 10, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/cancers10120483
Keywords
cancer drug sensitization; drug resistance; combination therapy; stem cell; cancer progenitor cell; cancer therapy; chemotherapy; epigenetics; methylation; histone modification
Categories
Funding
- American Cancer Society
Ask authors/readers for more resources
Cancer drug resistance is an enormous problem. It is responsible for most relapses in cancer patients following apparent remission after successful therapy. Understanding cancer relapse requires an understanding of the processes underlying cancer drug resistance. This article discusses the causes of cancer drug resistance, the current combination therapies, and the problems with the combination therapies. The rational design of combination therapy is warranted to improve the efficacy. These processes must be addressed by finding ways to sensitize the drug-resistant cancers cells to chemotherapy, and to prevent formation of drug resistant cancer cells. It is also necessary to prevent the formation of cancer progenitor cells by epigenetic mechanisms, as cancer progenitor cells are insensitive to standard therapies. In this article, we emphasize the role for the rational development of combination therapy, including epigenetic drugs, in achieving these goals.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available